ANNE FINLEY — Lobbyist Profile | Poliscope

ANNE FINLEY

Reported covered position: N/A

Filings

Clients

Firms

Years active

2007–2013

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
CELGENE CORPORATION	24	2007–2013

Lobbying firms

Firm	Filings	Years
CELGENE CORPORATION	24	2007–2013

Bills explicitly cited in this lobbyist’s assigned issues (16)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 2672

Preserving Access to Orphan Drugs Act of 2011

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Open original LDA filing ↗

Cited source text

- H.R. 1249/ S. 23, "Leahy-Smith America Invents Act", issues regarding patent reform. - PDUFA reauthorization - H.R.2672, S.1423, "Preserving Access to Orphan Drugs Act of 2011", regarding all provisions - Issues regarding PPACA implementation.

H.R. 2672

Preserving Access to Orphan Drugs Act of 2011

Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION

Open original LDA filing ↗

Cited source text

- H.R. 1249/ S. 23, "Leahy-Smith America Invents Act", issues regarding patent reform. - PDUFA reauthorization - H.R.2672, S.1423, "Preserving Access to Orphan Drugs Act of 2011", regarding all provisions - Issues regarding PPACA implementation.

Original LDA source filings (24)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

CELGENE CORPORATION via CELGENE CORPORATION

2013 · first_quarter · Q1

Firm income: —Client expense: $460,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

- Issues regarding PPACA implementation. - Issues regarding FDASIA implementation.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)

CELGENE CORPORATION via CELGENE CORPORATION

2012 · fourth_quarter · Q4

Firm income: —

Source: Senate LDA

Show 20 more original filings

CELGENE CORPORATION via CELGENE CORPORATION

2012 · first_quarter · Q1

Firm income: —Client expense: $250,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

- H.R. 1249/ S. 23, "Leahy-Smith America Invents Act", issues regarding patent reform. - PDUFA reauthorization - H.R.2672, S.1423, "Preserving Access to Orphan Drugs Act of 2011", regarding all provisions - Issues regarding PPACA implementation.

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Treasury, Dept of

CELGENE CORPORATION via CELGENE CORPORATION

2011 · fourth_quarter · Q4

Firm income: —Client expense: $240,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Treasury, Dept of

CELGENE CORPORATION via CELGENE CORPORATION

2011 · third_quarter · Q3

Firm income: —Client expense: $250,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2011 · second_quarter · Q2

Firm income: —Client expense: $140,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

-PPACA implementation, issues regarding the orphan drug definition for hcr fee

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2011 · first_quarter · Q1

Firm income: —Client expense: $325,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

-PPACA implementation, issues regarding the orphan drug definition for hcr fee

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2010 · third_quarter · 3A

Firm income: —Client expense: $290,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

- S. 1239/ H.R. 444, "340B Program Improvement and Integrity Act of 2009", regarding all provisions.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2010 · fourth_quarter · Q4

Firm income: —Client expense: $220,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

- S. 1239/ H.R. 444, "340B Program Improvement and Integrity Act of 2009", regarding all provisions.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2010 · third_quarter · 3A

Firm income: —Client expense: $290,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

- S. 1239/ H.R. 444, "340B Program Improvement and Integrity Act of 2009", regarding all provisions.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2010 · third_quarter · Q3

Firm income: —Client expense: $1,160,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

- S. 1239/ H.R. 444, "340B Program Improvement and Integrity Act of 2009", regarding all provisions.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2010 · second_quarter · Q2

Firm income: —Client expense: $120,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

- S. 1239/ H.R. 444, "340B Program Improvement and Integrity Act of 2009", regarding all provisions.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2010 · first_quarter · Q1

Firm income: —Client expense: $320,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Health care reform,

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2009 · fourth_quarter · Q4

Firm income: —Client expense: $160,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Health Care Reform, Veterans Health Care,

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

CELGENE CORPORATION via CELGENE CORPORATION

2009 · third_quarter · Q3

Firm income: —Client expense: $205,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

health care reform, VA benefits,

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

CELGENE CORPORATION via CELGENE CORPORATION

2009 · second_quarter · Q2

Firm income: —Client expense: $390,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

health care reform, patent reform, veterans' health

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

CELGENE CORPORATION via CELGENE CORPORATION

2009 · first_quarter · Q1

Firm income: —Client expense: $610,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Health Care reform, patent reform, veterans' health

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

CELGENE CORPORATION via CELGENE CORPORATION

2008 · fourth_quarter · Q4

Firm income: —Client expense: $125,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Pharmaceutical, biotechnology, veterans

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

CELGENE CORPORATION via CELGENE CORPORATION

2008 · third_quarter · Q3

Firm income: —Client expense: $70,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

pharmaceutical, biotech

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2008 · second_quarter · Q2

Firm income: —Client expense: $90,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

pharmaceutical, biotech

Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2008 · first_quarter · Q1

Firm income: —Client expense: $65,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

pharmaceutical, biotech

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

CELGENE CORPORATION via CELGENE CORPORATION

2007 · year_end · YY

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

pharmaceutical and biotechnology

Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE